Revenue

3 Months Ended

Dec. 31, 2020

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended
	December 31,
(In thousands)	2020		2019
Medical Device
Product sales	$	4,561	$	5,023
Royalties		7,909		8,898
Research, development and other		2,301		2,234
License fees		1,425		1,249
Total Revenue — Medical Device		16,196		17,404
In Vitro Diagnostics
Product sales		5,541		4,952
Research, development and other		560		260
Total Revenue — In Vitro Diagnostics		6,101		5,212
Total Revenue	$	22,297	$	22,616

Contract assets totaled $6.6 million and $6.1 million as of December 31, 2020 and September 30, 2020, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangements.